S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NYSE:PBH

Prestige Consumer Healthcare - PBH Stock Forecast, Price & News

$59.40
+0.05 (+0.08%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$58.77
$59.61
50-Day Range
$53.89
$61.12
52-Week Range
$51.70
$63.83
Volume
210,943 shs
Average Volume
274,653 shs
Market Capitalization
$2.97 billion
P/E Ratio
14.89
Dividend Yield
N/A
Price Target
$80.50

Prestige Consumer Healthcare MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
35.4% Upside
$80.50 Price Target
Short Interest
Bearish
2.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.57mentions of Prestige Consumer Healthcare in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
6.44%
From $4.19 to $4.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Consumer Discretionary Sector

172nd out of 366 stocks

Pharmaceutical Preparations Industry

195th out of 619 stocks

PBH stock logo

About Prestige Consumer Healthcare (NYSE:PBH) Stock

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $59.35 on Monday. The company has a market cap of $2.96 billion, a P/E ratio of 14.87, a P/E/G ratio of 1.77 and a beta of 0.50. The company has a quick ratio of 1.21, a current ratio of 2.09 and a debt-to-equity ratio of 0.93. Prestige Consumer Healthcare has a 52 week low of $51.70 and a 52 week high of $63.83. The business has a fifty day simple moving average of $57.68 and a 200-day simple moving average of $56.62.

Prestige Consumer Healthcare (NYSE:PBH - Get Rating) last issued its earnings results on Thursday, May 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.02. The firm had revenue of $266.94 million for the quarter, compared to analysts' expectations of $258.25 million. Prestige Consumer Healthcare had a return on equity of 13.27% and a net margin of 18.53%. The firm's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.79 earnings per share. Equities research analysts forecast that Prestige Consumer Healthcare will post 4.19 EPS for the current year.

Wall Street Analyst Weigh In

PBH has been the subject of several recent research reports. Jefferies Financial Group raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating and raised their price target for the stock from $65.00 to $70.00 in a research report on Tuesday, May 10th. Oppenheimer raised Prestige Consumer Healthcare from a "market perform" rating to an "outperform" rating and set a $63.00 price target for the company in a research report on Monday, May 9th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $80.50.

Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

PBH Stock News Headlines

Prestige Brands Holdings(PBH)
See More Headlines
Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

PBH Company Calendar

Last Earnings
11/04/2021
Today
8/08/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
CUSIP
74112D10
Employees
505
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.50
High Stock Price Forecast
$126.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+35.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$205.38 million
Pretax Margin
23.48%

Debt

Sales & Book Value

Annual Sales
$1.09 billion
Cash Flow
$4.84 per share
Book Value
$31.43 per share

Miscellaneous

Free Float
48,967,000
Market Cap
$2.97 billion
Optionable
Optionable
Beta
0.50

Key Executives

  • Mr. Ronald M. Lombardi (Age 58)
    Chairman, Pres & CEO
    Comp: $2.73M
  • Ms. Christine Sacco (Age 46)
    Chief Financial Officer
    Comp: $1.26M
  • Mr. Jeffrey Zerillo (Age 61)
    Sr. VP of Operations
    Comp: $580.88k
  • Mr. William C. P'Pool (Age 57)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $955.34k
  • Mr. Adel Mekhail (Age 61)
    Exec. VP of Marketing & Sales
    Comp: $971.47k
  • Mr. Philip David Terpolilli
    Director of Investor Relations
  • Dean Siegal
    Director of Communications
  • Ms. Mary Beth Fritz
    Sr. VP of Quality & Regulatory Affairs













PBH Stock - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBH shares.
View PBH analyst ratings
or view top-rated stocks.

What is Prestige Consumer Healthcare's stock price forecast for 2022?

4 brokers have issued 12-month target prices for Prestige Consumer Healthcare's shares. Their PBH stock forecasts range from $63.00 to $126.00. On average, they expect the company's share price to reach $80.50 in the next year. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for PBH
or view top-rated stocks among Wall Street analysts.

How has Prestige Consumer Healthcare's stock price performed in 2022?

Prestige Consumer Healthcare's stock was trading at $60.65 at the beginning of the year. Since then, PBH stock has decreased by 3.1% and is now trading at $58.78.
View the best growth stocks for 2022 here
.

When is Prestige Consumer Healthcare's next earnings date?

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PBH earnings forecast
.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) released its quarterly earnings data on Thursday, November, 4th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.03. The firm earned $276.23 million during the quarter, compared to the consensus estimate of $261.23 million. Prestige Consumer Healthcare had a net margin of 18.53% and a trailing twelve-month return on equity of 13.27%. The firm's quarterly revenue was up 16.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.78 earnings per share.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare updated its FY 2023 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $4.18-$4.23 for the period. The company issued revenue guidance of $1.12 billion-$1.13 billion, compared to the consensus revenue estimate of $1.12 billion.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (2.01%), Ophir Asset Management Pty Ltd (1.45%), Leeward Investments LLC MA (1.11%), Jennison Associates LLC (0.90%), North Star Asset Management Inc. (0.49%) and Assenagon Asset Management S.A. (0.42%). Insiders that own company stock include Mary Beth Fritz, Paton Brett and Ronald M Lombardi.
View institutional ownership trends
.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $58.78.

How much money does Prestige Consumer Healthcare make?

Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $2.93 billion and generates $1.09 billion in revenue each year. The company earns $205.38 million in net income (profit) each year or $3.99 on an earnings per share basis.

How many employees does Prestige Consumer Healthcare have?

Prestige Consumer Healthcare employs 505 workers across the globe.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266.

This page (NYSE:PBH) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.